GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » DeferredTaxAndRevenue

Lipigon Pharmaceuticals AB (OSTO:LPGO) DeferredTaxAndRevenue : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Lipigon Pharmaceuticals AB's current deferred tax and revenue for the quarter that ended in Dec. 2023 was kr0.00 Mil.

Lipigon Pharmaceuticals AB DeferredTaxAndRevenue Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB DeferredTaxAndRevenue Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial - - - - -

Lipigon Pharmaceuticals AB Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lipigon Pharmaceuticals AB DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipigon Pharmaceuticals AB (OSTO:LPGO) Business Description

Traded in Other Exchanges
Address
Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Headlines

No Headlines